71 results
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
29 Dec 23
Updated Interim Results for the Six Months Ended 30 June 2023
4:30pm
approach or the simplified approach, depending on the nature of the underlying group of financial assets.
General approach
The general approach
424B5
TLSA
Tiziana Life Sciences Ltd
1 Sep 23
Prospectus supplement for primary offering
5:16pm
of special general meetings, the general nature of the business to be considered.
Whenever stockholders are required to take any action at a meeting … capital asset, gain or appreciation or any tax in the nature of estate duty or inheritance tax, such tax shall not, until March 31, 2035, be applicable
6-K
EX-1.1
TLSA
Tiziana Life Sciences Ltd
1 Sep 23
Report of Foreign Private Issuer
4:46pm
in all jurisdictions in which the nature of the activities conducted by it or the character of the assets owned or leased by it makes such license … gross income and the value of its assets, the intended use of proceeds from the offering and sale of the Placement Shares and the nature
20-F/A
2022 FY
TLSA
Tiziana Life Sciences Ltd
13 Jun 23
Annual report (foreign) (amended)
12:37pm
approach, depending on the nature of the underlying group of financial assets.
General approach
The general approach is applied to the impairment … liabilities including the probability of pending and potential future litigation outcomes that, by their nature, are dependent on future events
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
25 May 23
Report of Foreign Private Issuer
7:01am
for Outstanding Research Achievement, Nature Biotechnology SciCafé, Nature Publications.
About Foralumab
Activated T cells play an important role
6-K
EX-99.2
0e0ar43y5d42s3w
29 Dec 22
Updated Interim Results for the Six Months Ended 30 June 2022
6:15pm
6-K
EX-99.2
rhqzlbxw
27 Dec 22
Interim Results for the Six Months Ended 30 June 2022
5:49pm
6-K
EX-99.1
hlu direff
11 Mar 22
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
7:23am
F-3/A
EX-5.1
o6i67o1baq w7roucrr3
25 Feb 22
Shelf registration (foreign) (amended)
4:10pm
6-K/A
EX-99.1
vjurqd
22 Feb 22
Interim Results for the Six Months Ended 30 June 2021
8:12am
8-K12B
EX-3.2
trvwn
21 Oct 21
Notification of registration of securities
9:17am
6-K
EX-99.1
a0ab27ergcr 68y22u
20 Oct 21
Report of Foreign Private Issuer
6:05am
6-K
EX-99.1
g554dq5uagqtxur
6 Oct 21
Current report (foreign)
11:14am
6-K
EX-99.1
0ew0v6a gx2o
5 Oct 21
Report of Foreign Private Issuer
11:40am
6-K
EX-99.1
brn 3utzbmvdevfcrb
4 Oct 21
Current Report of Private Issuer
8:22am
6-K
EX-99.1
mc8skmb5r4
28 Sep 21
Report of Foreign Private Issuer
6:13am
6-K
EX-99.1
ne5 5u7t4
21 May 21
Current Report
6:01am